Changzhou Qianhong BiopharmaLTD Management
Management criteria checks 3/4
Changzhou Qianhong BiopharmaLTD's CEO is Ke Wang, appointed in Sep 2014, has a tenure of 10.25 years. directly owns 5.07% of the company’s shares, worth CN¥398.21M. The average tenure of the management team and the board of directors is 3.9 years and 3.9 years respectively.
Key information
Ke Wang
Chief executive officer
CN¥1.3m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.3yrs |
| CEO ownership | 5.1% |
| Management average tenure | 3.9yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Do Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Warrant Your Attention?
Nov 18
Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Held Back By Insufficient Growth Even After Shares Climb 37%
Oct 21Here's Why Changzhou Qianhong BiopharmaLTD (SZSE:002550) Can Manage Its Debt Responsibly
Aug 21Changzhou Qianhong BiopharmaLTD (SZSE:002550) Has Affirmed Its Dividend Of CN¥0.12
May 26Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Looks Just Right With A 26% Price Jump
May 21Investors Can Find Comfort In Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Quality
May 02Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?
Mar 24CEO
Ke Wang (41 yo)
10.3yrs
Tenure
CN¥1,297,000
Compensation
Mr. Ke Wang serves as Non-Independent Director at Changzhou Qianhong Biopharma Co.,Ltd. since September 10, 2014 and serves as its General Manager since September 10, 2014.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | 10.3yrs | CN¥1.30m | 5.07% CN¥ 398.2m | |
| CFO & Board Secretary | no data | CN¥465.40k | 0.012% CN¥ 941.8k | |
| Deputy GM & Non-Independent Director | 7.3yrs | CN¥776.10k | 0.018% CN¥ 1.4m | |
| Chief Engineer & Director | 3.9yrs | CN¥556.00k | 0.015% CN¥ 1.2m | |
| Non-Independent Director & Deputy GM | no data | CN¥785.80k | no data | |
| Audit Director | less than a year | CN¥517.10k | 0.016% CN¥ 1.3m | |
| Deputy Director of Project Implementation Office & Non-Employee Supervisor | 3.9yrs | no data | 0.010% CN¥ 791.2k |
3.9yrs
Average Tenure
42yo
Average Age
Experienced Management: 002550's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | 10.3yrs | CN¥1.30m | 5.07% CN¥ 398.2m | |
| Deputy GM & Non-Independent Director | 7.3yrs | CN¥776.10k | 0.018% CN¥ 1.4m | |
| Chief Engineer & Director | no data | CN¥556.00k | 0.015% CN¥ 1.2m | |
| Non-Independent Director & Deputy GM | 3.9yrs | CN¥785.80k | no data | |
| Deputy Director of Project Implementation Office & Non-Employee Supervisor | 3.9yrs | no data | 0.010% CN¥ 791.2k | |
| Chairman of the Supervisory Board | less than a year | CN¥901.00k | 1.93% CN¥ 151.1m | |
| Chairman | 16.9yrs | CN¥369.50k | 20.44% CN¥ 1.6b | |
| Vice Chairman | 16.9yrs | CN¥526.60k | 7.87% CN¥ 617.3m | |
| Non-Independent Director & Deputy GM | less than a year | CN¥888.00k | no data | |
| Independent Director | 3.9yrs | CN¥100.00k | no data | |
| Independent Director | 3.9yrs | CN¥100.00k | no data | |
| Independent Director | less than a year | no data | no data |
3.9yrs
Average Tenure
52.5yo
Average Age
Experienced Board: 002550's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 17:49 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Changzhou Qianhong Biopharma CO.,LTD is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Yan | Changjiang Securities Co. LTD. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Mingrui Wang | Everbright Securities Co. Ltd. |